MA-VERACODE
6.10.2022 13:51:35 CEST | Business Wire | Press release
Veracode, a leading global provider of application security testing solutions, today announced the enhancement of its Continuous Software Security Platform to include container security. This early access program for Veracode Container Security is now underway for existing customers. The new Veracode Container Security offering, designed to meet the needs of cloud-native software engineering teams, addresses vulnerability scanning, secure configuration, and secrets management requirements for container images.
Veracode Chief Product Officer, Brian Roche, said, “As developers embrace cloud-native computing practices, containers have become increasingly important for business efficiency. This launch helps close a substantial gap in the market for developer-friendly solutions that cover critical capabilities for container security. We are excited to bring this next enhancement of our platform to the market and empower customers to address security testing for more modern architectures and deployment styles.”
The Requirement for Container Security is Rapidly on the Rise
Containers are increasingly used to simplify software deployment and runtime environment configuration management. They comprise small, fast, portable units of software in which code is packaged so that an application can be run quickly and reliably in different computing environments—from the desktop to the cloud. They provide an ecosystem of repositories, orchestration technologies, and capabilities that address related issues, such as service-to-service communication and configuration management. Instantiated in pipelines from code, containers have the benefit of immutability, meaning they are not updated, reconfigured or patched in production. Instead, the underlying image is updated with new capabilities and redeployed, helping to improve efficiency in the production environment.
Despite the benefits of containers, they are affected by many of the same problems that traditionally plague physical production or virtual server hardware, such as vulnerabilities introduced through additional software, poorly managed secrets (like Amazon Web Services keys and credentials in Dockerfiles), and security misconfigurations. This has resulted in increased demand for products that address these issues and related problems, with the Global Container Security Market size expected to reach $3.9 billion by 2027*. Container security scanning analyzes container images against organizational or industry-specific standards to identify insecure processes, misconfigurations that could lead to a vulnerability, and inadequate authentication and access control.
Veracode Container Security Integrates into the Developer Environment
Many products already in the market are aimed at securing containers in runtime and offer limited support for developers, posing a major challenge for early remediation. Veracode’s solution instead integrates into the CI/CD (continuous integration and continuous delivery) pipeline and is available at the command line interface. Providing coverage for vulnerability detection and remediation, secrets management, and security configuration issues on the most popular operating systems, it delivers remediation advice to developers early in the software development life cycle so that insecure containers don’t ship to production.
Veracode Container Security results are available in a variety of formats based on the user’s choice, including text, JSON (JavaScript Object Notation), and Software Bill of Materials (CycloneDX, SWID [Software Identification Tagging], or SPDX [Software Packaging Data Exchange]), making them easy to integrate with other tools. Providing developers and their teams with the tools to meet their specific needs means they can find and fix vulnerabilities early in the lifecycle, giving them confidence that their containerized application environment is secure.
“Veracode Container Security will be instrumental for our developers to ensure that the workloads they deploy into our cloud are secure,” said the Director of Information Security at an automotive company. “Without this tool, it would take our team weeks to receive and action container results and these would only have been available in limited formats. Now, we’re excited to integrate findings into the pipeline before they even move into production, creating time and cost efficiencies for our business.”
To learn more about Container Security, read more here.
*Research and Markets, "Global Container Security Market Size, Share & Industry Trends Analysis Report By Component (Products and Services), By Services Type, By Organization Size, By Vertical, By Regional Outlook and Forecast, 2021-2027" report, February 2022
About Veracode
Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities. Learn more at www.veracode.com, on the Veracode blog and on Twitter.
Copyright © 2022 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221006005542/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
